For citations:
Skripka AI, Bochkov PO, Akmalova KA, Shevchenko RV, Krupenin PM, Kogay VV, Listratov AI, Krainyaya AS, Napalkov DA, Gurinovich OS, Sokolova AA, Fomin VV, Sychev DA. Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. Meditsinskiy sovet = Medical Council. 2019;(21):65-73. (In Russ.) https://doi.org/10.21518/2079-701X-2019-21-65-73